Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
In this phase 2b, placebo-controlled trial involving patients with nonalcoholic steatohepatitis, pegozafermin, a long-acting glycopegylated FGF21 analogue, reduced fibrosis at 24 weeks.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2023-09, Vol.389 (11), p.998-1008 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1008 |
|---|---|
| container_issue | 11 |
| container_start_page | 998 |
| container_title | The New England journal of medicine |
| container_volume | 389 |
| creator | Loomba, Rohit Sanyal, Arun J. Kowdley, Kris V. Bhatt, Deepak L. Alkhouri, Naim Frias, Juan P. Bedossa, Pierre Harrison, Stephen A. Lazas, Donald Barish, Robert Gottwald, Mildred D. Feng, Shibao Agollah, Germaine D. Hartsfield, Cynthia L. Mansbach, Hank Margalit, Maya Abdelmalek, Manal F. |
| description | In this phase 2b, placebo-controlled trial involving patients with nonalcoholic steatohepatitis, pegozafermin, a long-acting glycopegylated FGF21 analogue, reduced fibrosis at 24 weeks. |
| doi_str_mv | 10.1056/NEJMoa2304286 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10718287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2864598406</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-e90f084a01f93d53b46da1371cd18e28d8751910d093dd86cba38c3df7116c2f3</originalsourceid><addsrcrecordid>eNp1kc1LAzEQxYMoWqtHr7IgggdXJx-bZE9Siq2KVvHjHNJNtm7Z3WjSFfSvN1IVFRwG5vB-PGbmIbSD4QhDxo8npxdXThMKjEi-gno4ozRlDPgq6gEQmTKR0w20GcIcYmGWr6MNKmjGgdIeGt_q1rimerPmMBm6duFdXVuT3PtK14krk8WjTUbjEcHJoNW1m3U2ubEz96ZL65uqTWJPBndnW2it1HWw25-zjx5Gp_fDs_Tyenw-HFymBQOxSG0OJUimAZc5NRmdMm40pgIXBktLpJEiwzkGA1E2khdTTWVBTSkw5gUpaR-dLH2fumljTWHjxrpWT75qtH9VTlfqt9JWj2rmXhQGgSWRIjocfDp499zZsFBNFQpb17q1rguKSJILYJxnEd37g85d5-MbPijOslzGP0cqXVKFdyF4W35vg0F9ZKR-ZRT53Z8nfNNfoURgfwk0TVCtnTf_GL0DmuKV-g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2864598406</pqid></control><display><type>article</type><title>Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH</title><source>MEDLINE</source><source>1990</source><source>EZB Electronic Journals Library</source><creator>Loomba, Rohit ; Sanyal, Arun J. ; Kowdley, Kris V. ; Bhatt, Deepak L. ; Alkhouri, Naim ; Frias, Juan P. ; Bedossa, Pierre ; Harrison, Stephen A. ; Lazas, Donald ; Barish, Robert ; Gottwald, Mildred D. ; Feng, Shibao ; Agollah, Germaine D. ; Hartsfield, Cynthia L. ; Mansbach, Hank ; Margalit, Maya ; Abdelmalek, Manal F.</creator><creatorcontrib>Loomba, Rohit ; Sanyal, Arun J. ; Kowdley, Kris V. ; Bhatt, Deepak L. ; Alkhouri, Naim ; Frias, Juan P. ; Bedossa, Pierre ; Harrison, Stephen A. ; Lazas, Donald ; Barish, Robert ; Gottwald, Mildred D. ; Feng, Shibao ; Agollah, Germaine D. ; Hartsfield, Cynthia L. ; Mansbach, Hank ; Margalit, Maya ; Abdelmalek, Manal F.</creatorcontrib><description>In this phase 2b, placebo-controlled trial involving patients with nonalcoholic steatohepatitis, pegozafermin, a long-acting glycopegylated FGF21 analogue, reduced fibrosis at 24 weeks.</description><identifier>ISSN: 0028-4793</identifier><identifier>ISSN: 1533-4406</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2304286</identifier><identifier>PMID: 37356033</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Allergy ; Biopsy ; Cholesterol ; Diabetes ; Diarrhea ; Double-Blind Method ; Electrocardiography ; Endocrinology ; Fatty liver ; Fibroblast Growth Factors - analogs & derivatives ; Fibrosis ; Fibrosis - drug therapy ; Fibrosis - etiology ; Fibrosis - pathology ; Gastroenterology ; Gastroenterology General ; Gastrointestinal Agents - administration & dosage ; Gastrointestinal Agents - therapeutic use ; High density lipoprotein ; Humans ; Hypertriglyceridemia ; Immunology ; Inflammation ; Inflammatory Disease ; Injections, Subcutaneous ; International organizations ; Liver cirrhosis ; Liver Disease ; Liver diseases ; Magnetic resonance imaging ; Metabolism ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - drug therapy ; Non-alcoholic Fatty Liver Disease - pathology ; Obesity ; Placebos ; Treatment Outcome ; Vital signs</subject><ispartof>The New England journal of medicine, 2023-09, Vol.389 (11), p.998-1008</ispartof><rights>Copyright © 2023 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2023 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c407t-e90f084a01f93d53b46da1371cd18e28d8751910d093dd86cba38c3df7116c2f3</citedby><cites>FETCH-LOGICAL-c407t-e90f084a01f93d53b46da1371cd18e28d8751910d093dd86cba38c3df7116c2f3</cites><orcidid>0000-0001-9486-1255 ; 0000-0002-4845-9991 ; 0000-0001-9872-2391</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2304286$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa2304286$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37356033$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Sanyal, Arun J.</creatorcontrib><creatorcontrib>Kowdley, Kris V.</creatorcontrib><creatorcontrib>Bhatt, Deepak L.</creatorcontrib><creatorcontrib>Alkhouri, Naim</creatorcontrib><creatorcontrib>Frias, Juan P.</creatorcontrib><creatorcontrib>Bedossa, Pierre</creatorcontrib><creatorcontrib>Harrison, Stephen A.</creatorcontrib><creatorcontrib>Lazas, Donald</creatorcontrib><creatorcontrib>Barish, Robert</creatorcontrib><creatorcontrib>Gottwald, Mildred D.</creatorcontrib><creatorcontrib>Feng, Shibao</creatorcontrib><creatorcontrib>Agollah, Germaine D.</creatorcontrib><creatorcontrib>Hartsfield, Cynthia L.</creatorcontrib><creatorcontrib>Mansbach, Hank</creatorcontrib><creatorcontrib>Margalit, Maya</creatorcontrib><creatorcontrib>Abdelmalek, Manal F.</creatorcontrib><title>Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In this phase 2b, placebo-controlled trial involving patients with nonalcoholic steatohepatitis, pegozafermin, a long-acting glycopegylated FGF21 analogue, reduced fibrosis at 24 weeks.</description><subject>Allergy</subject><subject>Biopsy</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Diarrhea</subject><subject>Double-Blind Method</subject><subject>Electrocardiography</subject><subject>Endocrinology</subject><subject>Fatty liver</subject><subject>Fibroblast Growth Factors - analogs & derivatives</subject><subject>Fibrosis</subject><subject>Fibrosis - drug therapy</subject><subject>Fibrosis - etiology</subject><subject>Fibrosis - pathology</subject><subject>Gastroenterology</subject><subject>Gastroenterology General</subject><subject>Gastrointestinal Agents - administration & dosage</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>High density lipoprotein</subject><subject>Humans</subject><subject>Hypertriglyceridemia</subject><subject>Immunology</subject><subject>Inflammation</subject><subject>Inflammatory Disease</subject><subject>Injections, Subcutaneous</subject><subject>International organizations</subject><subject>Liver cirrhosis</subject><subject>Liver Disease</subject><subject>Liver diseases</subject><subject>Magnetic resonance imaging</subject><subject>Metabolism</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Non-alcoholic Fatty Liver Disease - drug therapy</subject><subject>Non-alcoholic Fatty Liver Disease - pathology</subject><subject>Obesity</subject><subject>Placebos</subject><subject>Treatment Outcome</subject><subject>Vital signs</subject><issn>0028-4793</issn><issn>1533-4406</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kc1LAzEQxYMoWqtHr7IgggdXJx-bZE9Siq2KVvHjHNJNtm7Z3WjSFfSvN1IVFRwG5vB-PGbmIbSD4QhDxo8npxdXThMKjEi-gno4ozRlDPgq6gEQmTKR0w20GcIcYmGWr6MNKmjGgdIeGt_q1rimerPmMBm6duFdXVuT3PtK14krk8WjTUbjEcHJoNW1m3U2ubEz96ZL65uqTWJPBndnW2it1HWw25-zjx5Gp_fDs_Tyenw-HFymBQOxSG0OJUimAZc5NRmdMm40pgIXBktLpJEiwzkGA1E2khdTTWVBTSkw5gUpaR-dLH2fumljTWHjxrpWT75qtH9VTlfqt9JWj2rmXhQGgSWRIjocfDp499zZsFBNFQpb17q1rguKSJILYJxnEd37g85d5-MbPijOslzGP0cqXVKFdyF4W35vg0F9ZKR-ZRT53Z8nfNNfoURgfwk0TVCtnTf_GL0DmuKV-g</recordid><startdate>20230914</startdate><enddate>20230914</enddate><creator>Loomba, Rohit</creator><creator>Sanyal, Arun J.</creator><creator>Kowdley, Kris V.</creator><creator>Bhatt, Deepak L.</creator><creator>Alkhouri, Naim</creator><creator>Frias, Juan P.</creator><creator>Bedossa, Pierre</creator><creator>Harrison, Stephen A.</creator><creator>Lazas, Donald</creator><creator>Barish, Robert</creator><creator>Gottwald, Mildred D.</creator><creator>Feng, Shibao</creator><creator>Agollah, Germaine D.</creator><creator>Hartsfield, Cynthia L.</creator><creator>Mansbach, Hank</creator><creator>Margalit, Maya</creator><creator>Abdelmalek, Manal F.</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9486-1255</orcidid><orcidid>https://orcid.org/0000-0002-4845-9991</orcidid><orcidid>https://orcid.org/0000-0001-9872-2391</orcidid></search><sort><creationdate>20230914</creationdate><title>Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH</title><author>Loomba, Rohit ; Sanyal, Arun J. ; Kowdley, Kris V. ; Bhatt, Deepak L. ; Alkhouri, Naim ; Frias, Juan P. ; Bedossa, Pierre ; Harrison, Stephen A. ; Lazas, Donald ; Barish, Robert ; Gottwald, Mildred D. ; Feng, Shibao ; Agollah, Germaine D. ; Hartsfield, Cynthia L. ; Mansbach, Hank ; Margalit, Maya ; Abdelmalek, Manal F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-e90f084a01f93d53b46da1371cd18e28d8751910d093dd86cba38c3df7116c2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allergy</topic><topic>Biopsy</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Diarrhea</topic><topic>Double-Blind Method</topic><topic>Electrocardiography</topic><topic>Endocrinology</topic><topic>Fatty liver</topic><topic>Fibroblast Growth Factors - analogs & derivatives</topic><topic>Fibrosis</topic><topic>Fibrosis - drug therapy</topic><topic>Fibrosis - etiology</topic><topic>Fibrosis - pathology</topic><topic>Gastroenterology</topic><topic>Gastroenterology General</topic><topic>Gastrointestinal Agents - administration & dosage</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>High density lipoprotein</topic><topic>Humans</topic><topic>Hypertriglyceridemia</topic><topic>Immunology</topic><topic>Inflammation</topic><topic>Inflammatory Disease</topic><topic>Injections, Subcutaneous</topic><topic>International organizations</topic><topic>Liver cirrhosis</topic><topic>Liver Disease</topic><topic>Liver diseases</topic><topic>Magnetic resonance imaging</topic><topic>Metabolism</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Non-alcoholic Fatty Liver Disease - drug therapy</topic><topic>Non-alcoholic Fatty Liver Disease - pathology</topic><topic>Obesity</topic><topic>Placebos</topic><topic>Treatment Outcome</topic><topic>Vital signs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Sanyal, Arun J.</creatorcontrib><creatorcontrib>Kowdley, Kris V.</creatorcontrib><creatorcontrib>Bhatt, Deepak L.</creatorcontrib><creatorcontrib>Alkhouri, Naim</creatorcontrib><creatorcontrib>Frias, Juan P.</creatorcontrib><creatorcontrib>Bedossa, Pierre</creatorcontrib><creatorcontrib>Harrison, Stephen A.</creatorcontrib><creatorcontrib>Lazas, Donald</creatorcontrib><creatorcontrib>Barish, Robert</creatorcontrib><creatorcontrib>Gottwald, Mildred D.</creatorcontrib><creatorcontrib>Feng, Shibao</creatorcontrib><creatorcontrib>Agollah, Germaine D.</creatorcontrib><creatorcontrib>Hartsfield, Cynthia L.</creatorcontrib><creatorcontrib>Mansbach, Hank</creatorcontrib><creatorcontrib>Margalit, Maya</creatorcontrib><creatorcontrib>Abdelmalek, Manal F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Consumer Health Database</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library (ProQuest)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loomba, Rohit</au><au>Sanyal, Arun J.</au><au>Kowdley, Kris V.</au><au>Bhatt, Deepak L.</au><au>Alkhouri, Naim</au><au>Frias, Juan P.</au><au>Bedossa, Pierre</au><au>Harrison, Stephen A.</au><au>Lazas, Donald</au><au>Barish, Robert</au><au>Gottwald, Mildred D.</au><au>Feng, Shibao</au><au>Agollah, Germaine D.</au><au>Hartsfield, Cynthia L.</au><au>Mansbach, Hank</au><au>Margalit, Maya</au><au>Abdelmalek, Manal F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2023-09-14</date><risdate>2023</risdate><volume>389</volume><issue>11</issue><spage>998</spage><epage>1008</epage><pages>998-1008</pages><issn>0028-4793</issn><issn>1533-4406</issn><eissn>1533-4406</eissn><abstract>In this phase 2b, placebo-controlled trial involving patients with nonalcoholic steatohepatitis, pegozafermin, a long-acting glycopegylated FGF21 analogue, reduced fibrosis at 24 weeks.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>37356033</pmid><doi>10.1056/NEJMoa2304286</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-9486-1255</orcidid><orcidid>https://orcid.org/0000-0002-4845-9991</orcidid><orcidid>https://orcid.org/0000-0001-9872-2391</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2023-09, Vol.389 (11), p.998-1008 |
| issn | 0028-4793 1533-4406 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10718287 |
| source | MEDLINE; 1990; EZB Electronic Journals Library |
| subjects | Allergy Biopsy Cholesterol Diabetes Diarrhea Double-Blind Method Electrocardiography Endocrinology Fatty liver Fibroblast Growth Factors - analogs & derivatives Fibrosis Fibrosis - drug therapy Fibrosis - etiology Fibrosis - pathology Gastroenterology Gastroenterology General Gastrointestinal Agents - administration & dosage Gastrointestinal Agents - therapeutic use High density lipoprotein Humans Hypertriglyceridemia Immunology Inflammation Inflammatory Disease Injections, Subcutaneous International organizations Liver cirrhosis Liver Disease Liver diseases Magnetic resonance imaging Metabolism Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - pathology Obesity Placebos Treatment Outcome Vital signs |
| title | Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A29%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized,%20Controlled%20Trial%20of%20the%20FGF21%20Analogue%20Pegozafermin%20in%20NASH&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Loomba,%20Rohit&rft.date=2023-09-14&rft.volume=389&rft.issue=11&rft.spage=998&rft.epage=1008&rft.pages=998-1008&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2304286&rft_dat=%3Cproquest_pubme%3E2864598406%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2864598406&rft_id=info:pmid/37356033&rfr_iscdi=true |